Cross-Sector entity
AtriCure is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The clearest coverage concentration is earnings: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention IAMGOLD, all published on February 18, 2026.
3 verified stories tracked
Last mentioned: Feb 18, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 67 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
AtriCure is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The clearest coverage concentration is earnings: 2 of 3 stories, with the rest divided among 1 other category. We currently track 3 Cross-Sector stories that mention IAMGOLD, all published on February 18, 2026. Each carries 5 original sources on average.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IAMGOLD. Shared-story counts are live from our verified record — not editorial picks.
MFA Financial, BrightSpire Capital, and IAMGOLD reported fourth-quarter 2025 results, highlighting a complex landscape of stabilizing mortgage credit and commercial real estate repositioning. While the REITs navigate interest rate normalization, IAMGOLD is capitalizing on operational ramp-ups at its flagship Côté Gold project.
Source: finance.yahoo.com · finance.yahoo.com
A diverse group of mid-to-large cap companies across mining, energy, and healthcare reported stronger-than-expected quarterly results, signaling robust operational efficiency. IAMGOLD and EQT Corporation headlined the session with significant revenue outperformance, reflecting strength in commodity and energy markets.
Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Source: Seeking Alpha · Seeking Alpha
